Navigation Links
Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
Date:5/19/2008

SAN DIEGO, May 19 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of therapeutic oxygen transport agents today announced that it has completed enrollment in the second Phase III trial of its lead product, Hemospan(R).

Sangart expects the top line results from this trial to be available in the second half of 2008.

The 370-patient randomized, double-blind, controlled Phase III study was conducted at 18 clinical sites in six European countries. Together with another Phase III study completed in March, the trials were designed to evaluate the safety and efficacy of Hemospan for preventing and treating hemodynamic instability, particularly hypotension, or low blood pressure, during primary hip replacement surgery.

Dr. Robert Winslow, Chairman, President and CEO of Sangart, commented, "The completed enrollment in this second Phase III trial represents another significant milestone for Sangart as we advance the development of Hemospan."

No similar oxygen transport agents are currently on the market in Europe or the United States. Extensive preclinical efficacy studies and earlier clinical trials indicate that Hemospan's novel oxygen delivery mechanism has the potential to enhance oxygenation of ischemic tissues and may provide a safe and effective alternative to blood transfusion, especially when blood is not immediately available.

About Sangart

Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as therapeutic oxygen transport agents and potential alternatives to blood transfusions.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-f
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
2. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
3. China-Biotics, Inc. Completes Foundation for Its New Plant
4. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
5. EUSA Pharma Completes Acquisition Of Cytogen Corporation
6. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
7. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
10. Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
11. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... 30, 2014 Applying a well-known optical phenomenon ... Harvard University has demonstrated the ability to "paint" ... that holds promise for making future, flexible electronic ... sides of next-gen rocket ships and spacecraft with ... through oil in water, it becomes iridescent, revealing ...
(Date:9/30/2014)... bio-mimicking analog of one of nature,s most efficient ... team led by Alejandro Briseno of the University ... in developing long-sought polymer architecture to boost power-conversion ... electronic devices. , Briseno, with colleagues and ... Stanford University and Dresden University of Technology, Germany, ...
(Date:9/30/2014)... 2014 Report Details Biosimilar drugs ... revenues Do you want to find sales potentials ... predictions for those biological drugs from 2014, helping ... financial data, R&D trends, opportunities and selling prospects. ... to 2024 at overall world market, therapeutic class, ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... LI-COR(R) Biosciences announces,an enhanced matching funds ... $1.75 million in matching funds is available ... each qualifying institution. The,Genomics Education Matching Funds ... to help colleges acquire LI-COR DNA sequencing ...
... PharmBIO Products Launches Unique Online Configurator For the ... ... Gore PharmBIO Products has,launched an industry first -- an ... configuring fluid,assemblies for biopharmaceutical manufacturers., The GORE(TM) STA-PURE(SM) Bioprocess ...
... support advancement to Phase 2 -, - Results of ... BRISBANE, Calif., Sept. 24 InterMune, Inc.,(Nasdaq: ... and,in-vitro studies of ITMN-191 (R7227) accepted for presentation at ... Study of Liver Diseases,(AASLD, Oct. 31 - Nov. 4 ...
Cached Biology Technology:Gore's Legacy of Innovation Extends From Products to Processes 2Gore's Legacy of Innovation Extends From Products to Processes 3InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 2InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 3InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 4InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 5InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 6
(Date:9/30/2014)... runoff in Hawaii is causing tumors in endangered sea ... published Tuesday in the peer-reviewed open-access journal PeerJ ... in algae that the turtles eat, promoting the formation ... organs. , Scientists at Duke University, the University of ... conducted the study to better understand the causes ...
(Date:9/30/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich report that a new ... sensitive to chemotherapeutic drugs. They have also pinpointed ... target for anti-tumor agents. , Researchers led ... Sieber of the Technische Universitt Mnchen have identified ... new weapon in the fight against malignant tumors. ...
(Date:9/30/2014)... with IVF? Here,s some hope: A new research report ... FASEB Journal , explains how scientists developed a ... which induced embryo development in human and mouse eggs ... the sperm cell during fertilization. , "We believe that ... shift in our understanding of human fertilization by providing ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... significantly advance our understanding of the genetic basis of ... past year. They are the users of a web-based ... McGill School of Computer Science and collaborator Mathieu Blanchette. ... contribute to scientific research by arranging multiple sequences of ...
... fruit flies use to sense heat and chemicals may someday ... mosquitoes. , In the current issue of Nature , ... at Brandeis University and his team, spearheaded by KyeongJin Kang ... flies distinguish the warmth of a summer day from the ...
... 2011   Security Management Systems (SMS) , a ... an advanced data center security system for Oracle ... Services Corporation. Based in Somerset, New ... providing Oracle-based business operations solutions and information systems, ...
Cached Biology News:Video game players advancing genetic research 2Addressing pain and disease on the fly 2Security Management Systems (SMS) Completes Oracle Data Center Security Project for Core Services Corporation 2Security Management Systems (SMS) Completes Oracle Data Center Security Project for Core Services Corporation 3
... temperature control for microbiology and cell culture. ... is suitable for DASGIP bioreactors from 150 ... temperature ranges from approximately 10 °C to ... with an individual electrical heating element with ...
... gel stain is a sensitive nucleic acid ... to RNA and low background in gels, making ... polyacrylamide gels using laser scanners or standard UV ... mL unit size (S-7568) and a special packaging ...
... reports the data from any one of IITC ... recorder. The final data is sent from the ... is automatic for Systolic, Mean, Heart Rate while ... is always in the position to override the ...
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
Biology Products: